A Phase 2 interventional study of FB102 and Placebo in Celiac Disease, sponsored by Forte Biosciences, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Forte Biosciences, Inc. (part of argenx) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Celiac Disease with a site in Australia — 2 open to participants now, 4 under way, none of them phase 3. Celiac Disease · Australia.
Among the 16 studies in Celiac Disease with a site in Australia, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 in phase 2, and was the 15th registered.
352 studies on the registry are indexed under Celiac Disease; 77 are open to participants now.
Browse Celiac Disease studies →2 of the 16 studies in Celiac Disease with a site in Australia are open now. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in Australia, United States, New Zealand
Ages 18–75
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10
First in 2007; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 100 is above the median of 50 across 214 interventional studies indexed under Celiac Disease.
Median enrollment 54 across the 15 interventional studies, 20 across the 1 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Forte Biosciences, Inc., one of the names counted as argenx. Under that name alone:
Forte Biosciences, Inc. is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
argenx has 1 study filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Celiac Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982963Forte Biosciences, Inc.Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease | 2027-02-28 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Celiac Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo controlled clinical study to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of FB102 in adult participants with well controlled (on a strict GFD) CeD following an oral gluten challenge.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FB102
Biological: FB102
FB102
Biological: FB102
Placebo
Other: Placebo
FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio.
Placebo
Change from baseline in the VCIEL
Vh:Cd and IEL Composite Scale (VCIEL)
Time frame: 78 Days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.
Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FB102